AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Xeris Biopharma Stock Soars 12.02% on Record Q2 Earnings
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Aug 7, 2025 8:29 am ET1min read
Aime SummaryXeris Biopharma's stock surged 12.02% in pre-market trading on August 7, 2025, driven by the company's impressive financial performance and strategic initiatives.
Xeris Biopharma reported record financial results for the second quarter of 2025, with total revenue increasing by 49% year-over-year to $71.5 million. This growth was primarily driven by a 136% increase in Recorlev® revenue, reflecting a significant rise in patient demand. The company also raised its full-year 2025 total revenue guidance to $280-$290 million, up from the previous range of $260-$275 million.
During the quarter,
hosted its first-ever Analyst and Investor Day, where it outlined a long-term vision and growth strategy. The company guided to $750 million in total revenue by 2030, with expectations for Recorlev® to reach nearly $1 billion in net revenue by 2035. Additionally, the potential peak net revenue for XP-8121 was highlighted at $1-$3 billion, underscoring the company's accelerated growth trajectory and commitment to value creation.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Standard BioTools Inc. plunged 11.01% due to delayed clinical trial submissions and supply chain disruptions.
Dec.24 2025
United States Antimony Corporation shares surge 7.87% on operational advancements and sector tailwinds
Dec.24 2025
SEALSQ Shares Plunged 5.88% in Pre-Market Trading on Dec. 24 2025 as Heightened Investor Caution Ahead of Year-End Holiday Weighs
Dec.24 2025
ASST plunges 6.98% in pre-market as Bitcoin strategy volatility and market challenges weigh
Dec.24 2025
Poet Technologies (NASDAQ: POET) Falls 6.04% as Investor Caution Ahead of AI Infrastructure Execution Phase
Dec.24 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet